Anavex Ny tråd feb. 2023 - Nyt Parkinsonforsøg i Australien!
-
Tak for forklaringen Boersboe.
Jeg ved godt man aldrig kan tage 1:1 fra andre studier. Tilfældigt eller ej, så har jeg flere gange set - typisk mindre selskaber med begrænset likviditet - designe mindre fase 2B/3 studer som ender med at fejle
Da Anavex designede det pågældende studie havde de bare data fra 32 AD patienter. De er hvis det jeg vil kalde til den tyde side at designe et pivotalt CNS studie.
Er FDA gået væk fra at kræve der skal være pivotalt forsøg fra US? Avavex har kun studier i AUS
FDA synes de senest år at have løsnet grebet på hvad der kan godkendes. Herunder også i AD. Det kan man så have forskellige holdninger til. Her og nu er det "det nye sort"
Novo har haft stort 5-cifret antal patienter igennem + 68 ugers diabetes og fedme studier. Så de må have set noget i de studier der efterfølgende har fået dem til at validere i præklinik og så scale til fase 3
-
Det var længe inden Covid
CT har det listet i perioden 2014-2018. Og man forlængede så med 21 personer ud af de 32. -
Anavex 8-K ændringer i ledelsen!
CEOen kan ikke også være formand for bestyrelsen!
Umiddelbar et positivt tiltag, at magten er sikkert en sund fordeling.
Missling er pt kun CEO og kan således ikke også blive formand.
Ren spekulation fra min side!!! Kunne evt. være et led/krav i forbindelse med en kommende partneraftale???
Måske mister Missling sin plads i bestyrelsen og forbliver kun som CEO???
RENT GÆTTERI FRA MIN SIDE!!!Udskrift fra bestyrelsesmøde den 11. April 2023:
On
April 11, 2023, the Board of Directors (the "Board
") of Anavex Life
Sciences Corp., a Nevada corporation (the "Company
"), determined that it
was in the best interests of the Company and its stockholders to amend and restate the Company's Bylaws, and approved and
adopted the Amended and Restated Bylaws of the Company (the "Amended and Restated
Bylaws"). The Board amended the Company's Bylaws to require that the position of Chairman of the Board of
Directors must be filled by an independent director and cannot be held by the Chief Executive Officer of the Company. The Amended
and Restated Bylaws became effective immediately upon their adoption. -
No probs TDT
-
Anavex Missling er både bestyrelsesformand og CEO iflg. dette link!
Christopher Missling Ph.D.
Chairman of the Board, President, Chief Executive Officer, Company SecretaryDette betyder, at der skal ske en ændring på formandsposten eller CEO til GF den 23. maj.
Hvis der udskiftes på formandsposten, skal dette indstilles inden for de næste dage, da det er aktionærerne der via. afstemning giver mandat til denne post - proxyen udsendes her i april.
Spændende hvorfor man netop nu laver denne ændring og hvilken post Missling må afgive og til hvem.
Hvis vi snakker et kommende partnerskab, som Anavex har varslet i forbindelse med Alzheimer og Parkinson, så ville det nok være naturligt at en kommende partner fik en post i bestyrelsen - afhængig af omfanget af aftalen?Men igen ren spekulation fra min side! - måske er dette bare en almindelig og fornuftig tilpasning af forretningsorden.
I min virksomhed er formandsposten og det der svarer til CEO´en adskilt jf. vedtægterne. -
Ret beset er det en tåbelig konstruktion set fra aktionærernes side, at de to poster er besat af en og samme mand.
Hvis jeg var Missling ville jeg tage formandsposten, hvor magten ligger.
Men interessant at se de næste måneder.
Endnu en gang er mit håb, at en partneraftale tømmer tarmen på shorterne (undskyld sproget).
-
Darvin , det kan man åbenbart godt, kan ikke forstille mig at de gør ting som er ulovlige.
Her er lidt om emmet:
https://www.glasslewis.com/wp-content/uploads/2016/03/2016-In-Depth-Report-INDEPENDENT-BOARD-CHAIRMAN.pdfDer er helt sikket positivt at der kommer en uafhængig bestyrelse formand som kan rette firmaet ind hvis han er utilfreds med noget, eller med andre ord: Give CEO en skideballe eller værre, fyre ham i grove tilfælde.
Mandag morgen US 0800am ET på den årlige Needham healthcare konference vil Missling snakke (igen & igen).
Jeg vil blive meget skuffet (igen & igen) hvis han bare giver den same smøre og ikke kommer med noget nyt. Der er jo ingen grund til at møde op hvis han ikke kommer med nyt men kan bare henvise til den sidste.Hvis der ikke kommer noget nyt af betydning før aktionær mødet (eller på mødet) er det måske en god ide at Missling møder op med 2 store bevæbnede bodyguards med mindre han er masochist.
-
This is not illegal in the United States. It's actually beneficial in early phases to have the roles filled by the same person.
With that said, I am extremely pleased that Jiong Ma is taking a more key role in the company.
-
Anavex Jiong Ma erstatter Missling som formand!
Missling er stadig CEO - udpegningen af en uafhængig og kompetent ny formand i stedet for Missling kan næsten kun ses positivt.
Giver nuværende og evt. nye aktionærer (og evt. kommende partner), en øget tillid til, at aktionæres interesser sandsynligvis varetages bedre - især når selskabet forhåbentlig står over for en større udvikling.
Missling har haft "for mange hatte på" og kan derfor nemt glemme aktionærene, som den mangelfulde kommunikation især i de senere år har givet indtryk af.
Jiong Ma synes at være den kompetente "voksen", der kan få sat lidt styr på tingene.Udsendt proxy for det kommende aktionærmøde den 23. Maj 2023:
http://www.viewproxy.com/Anavex/2023/ProxyStatement2023.pdf
Vigtigheden af en uafhængig formand:
Director Independence.
Under the NASDAQ Stock Market Rules, the Board has a responsibility to make an affirmative determination that those members of its Board that serve as independent directors do not have any relationships with the Company and its businesses that would impair their independence. The Board has determined that that Christopher Missling, PhD is not independent as that term is defined by NASDAQ 5605(a)(2) because Dr. Missling serves as our President, Chief Executive Officer, and Secretary.Udpegning af Dr. Jiong Ma som ny formand:
Board Leadership Structure. The Board of Directors is composed of a majority of independent directors and the Chief Executive Officer of the Company.
Our Board of Directors has appointed an independent Board Chair, Dr. Jiong Ma. As Board Chair, Dr. Ma has the authority, among other things, to call and preside over meetings of our Board, to set meeting agendas, and to determine materials to be distributed to the Board. The Company believes that separation of the positions of Board Chair and Chief Executive Officer reinforces the independence of our Board in its oversight of the business and affairs of the Company. In addition, the Company believes that having an independent Board Chair creates an environment that is more conducive to objective evaluation and oversight of management's performance, increasing management accountability and improving the ability of our Board to monitor whether management's actions are in the best interests of the Company and its stockholders.Jiong Ma baggrund:
Jiong Ma, PhD. Jiong Ma, age 59, is a senior board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in digital health, technology and the new energy transition. Dr. Jiong Ma currently serves on the board of SES AI Corporation (NYSE: SES), and LinkinVax, a biotech company, spin-off from the Vaccine Research Institute in France. Dr. Ma served as Senior Partner and member of the investment committee at Braemar Energy Ventures ("Braemar"). While at Braemar, Dr. Ma has led investments in more than 15 companies involved in either resource efficiency, e-mobility, industrial digitalization, renewable energy, or deep tech, and have achieved multiple successful exists through M&A and IPO. Dr. Ma has significant knowledge and expertise in the technology industry, including information security. Prior to Braemar Energy Ventures, she was with the Venture Capital Group at 3i Group, a global private equity firm, where she led investments across multiple stages in Digital Health, TMT and Cleantech. Preceding the Venture Capital Group at 3i, Dr. Ma held several senior positions at Lucent Technologies and Bell Labs. Her responsibilities included lead roles in product portfolio strategy, new product launches for Optical and Data Networking, and research and product development. Dr. Ma was also a founding team member of Onetta Inc., a fiber networks company. She has a PhD in Electrical and Computer Engineering from the University Colorado at Boulder and an MS in Electrical Engineering from Worcester Polytechnic Institute. Dr. Ma is a Kauffman Fellow.
-
She is taking the Chairman spot. Missling will remain CEO.
-
"In addition, the Company believes that having an independent Board Chair creates an environment that is more conducive to objective evaluation and oversight of management's performance, increasing management accountability and improving the ability of our Board to monitor whether management's actions are in the best interests of the Company and its stockholders."
Aldeles fornuftigt. Forhåbentlig betyder sidste linje at der kommer noget mere fart på.
-
Tålmodighed
Anavex Life Sciences Corp (AVXL): "I get tired of waiting for someone else...
RedShoulder: "I get tired of waiting for someone else to make me rich. But then I think about having to do it myself and I become a bit more patient." Classic.
InvestorsHub (investorshub.advfn.com)
-
Anavex Positiv Nedmann konference den 17. april - men ikke meget nyt!
Bundlinje:
Missling gentager at både primære og sekundære endpoints blev opnået i Alzheimer fase 2/3.
Afventer Peer Review, da denne ventes anvendt til at diskuterer med myndighederne om næste skridt - markedsgodkendelse.
Missling påstår også, at Anavex`s resultater er bedre end det vi har set fra ALLE andre - også fra BIIB/EISAI!Forventer kommercialisering på sigt i AD, Parkinson og RETT i US, Asien og EU mm., som følge af de resultater de har haft og afventer.(Skal han nok sige, ellers giver det vel ingen mening at forsætte!)
Ellers stort set en gentagelse af sidste konference i januar, hvilket ikke er negativt - men der er stadig ingen tidsplan, hvornår vi kan vente resultater og hvornår div. længe proklamererede forsøg i Parkinson, PDD, Fragile X og den anden "hemmelige" og sjældne indikation mm.
Heller ikke nogen tidsplan for 3-71`s videre forløb.Lyder stadig meget overbevist om, at 2-73 virker, men tror ikke der sker meget før Peer Reviewet fra AD fase 2/3.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind